CLINICAL TRIALS PROFILE FOR TOPROL-XL
✉ Email this page to a colleague
All Clinical Trials for TOPROL-XL
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00038077 ↗ | Reversal of Ventricular Remodeling With Toprol-XL | Completed | AstraZeneca | Phase 3 | 2001-08-01 | The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease. |
NCT00123903 ↗ | COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria | Terminated | GlaxoSmithKline | Phase 3 | 2005-07-01 | This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria. |
NCT00241904 ↗ | Reducing Total Cardiovascular Risk in an Urban Community | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 4 | 2006-05-01 | PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOPROL-XL
Condition Name
Clinical Trial Locations for TOPROL-XL
Trials by Country
Clinical Trial Progress for TOPROL-XL
Clinical Trial Phase
Clinical Trial Sponsors for TOPROL-XL
Sponsor Name